Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Top Drug Maker Cipla Ropes In Teva’s Tim Crew As U.S. Plans Take Shape

This article was originally published in PharmAsia News

Executive Summary

After hiring Teva’s Frank Pieters and Novartis’ Subhanu Saxena, Cipla has now roped in Teva’s Tim Crew to play a key role in its U.S. plans. Many see it as a sustained effort to bring in higher management bandwidth.

You may also be interested in...



Overhauling Teva: Conversations With Jeremy Levin And Michael Hayden

Teva CEO Jeremy Levin and the CSO he hired, Michael Hayden, want to re-focus the company on innovative R&D and selective generics opportunities, and that means an overhaul of the R&D organization and new priorities for business development. Levin and Hayden spoke to IN VIVO about their goals and shaping these activities following a widely anticipated investor briefing on December 11 in New York City.

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Lee Takes India Compulsory License Fight To Saxagliptin

In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.

Topics

Related Companies

UsernamePublicRestriction

Register

OM006145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel